Trial reportNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2023
Transcutaneous Auricular Vagus Nerve Stimulation (ta-VNS) for Treatment of Drug-Resistant Epilepsy: A Randomized, Double-Blind Clinical Trial.
Trial report in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Transcutaneous auricular vagus nerve stimulation may improve cognitive deficits in neuropsychiatric diseases-a systematic review.Frontiers in aging neuroscience · 2026Pooled it
- Research hotspots and trends of non-invasive vagus nerve stimulation: a bibliometric analysis from 2004 to 2023.Frontiers in neurology · 2024Pooled it
- Effectiveness of transcutaneous auricular vagus nerve stimulation in stroke rehabilitation: a systematic review and meta-analysis of randomized clinical trials.Frontiers in neurologyPooled it
- Effect of transcutaneous vagus nerve stimulation in hemodialysis patients: A randomized controlled trial.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2026Trial
- Postoperative pain after joint replacement surgery : A randomized controlled trial of transcutaneous auricular vagus nerve stimulation and the role of depression and anxiety.Orthopadie (Heidelberg, Germany) · 2026Trial
- Transcutaneous Auricular Vagus Nerve Stimulation for Postpartum Contraction Pain During Elective Cesarean Delivery: A Randomized Clinical Trial.JAMA network open · 2025Trial
- Transcutaneous auricular vagus nerve stimulation to treat narcolepsy type 1 (TARGET-NT1): A two-arm, randomised, sham-controlled trial.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Trial
- Evidence of bottom-up homeostatic modulation induced taVNS during emotional and Go/No-Go tasks.Experimental brain research · 2024Trial
- Transcutaneous auricular vagus nerve stimulation in drug-resistant epilepsy: A randomized, sham-controlled crossover trial with exploratory EEG and MRI response phenotyping.Epilepsia open · 2026Article
- Neurocardiology: Brain-Heart Interactions in the Heart.MedComm · 2026Review
- Non-invasive Vagal Nerve Stimulation as a Potential Treatment for Repetitive Blast Trauma.bioRxiv : the preprint server for biology · 2026Article
- Article
- Article
- Efficacy of Transcutaneous Auricular Vagus Nerve Stimulation for Postoperative Pain Relief in Patients Undergoing Elective Laparoscopic Gastrointestinal Tumor Surgery.Pain and therapy · 2026Article
- Article
- Assessing the efficacy and safety of transcranial magnetic stimulation and vagus nerve stimulation for drug-resistant epilepsy: A systematic review.Surgical neurology international · 2026Review
- Effects of transcutaneous auricular vagus nerve stimulation on patients with post-stroke insomnia: a randomized controlled trial protocol.Frontiers in psychiatry · 2026Article
- Transcutaneous auricular vagus nerve stimulation: mechanisms, applications, and research progress.Frontiers in neuroscience · 2026Review
- A sham-controlled randomised trial evaluating the safety, acceptability, and efficacy of autonomic neuromodulation using transcutaneous vagal sensory stimulation in uncontrolled hypertensive patients: rationale and study design of the SCRATCH-HTN study.Frontiers in cardiovascular medicine · 2026Article
- Effect of carbamazepine and levetiracetam on coagulation parameters: Prothrombin time, activated partial thromboplastin time, D-dimer, and fibrinogen levels.Journal of medical biochemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
Abstract
This study explored the efficacy and safety of transcutaneous auricular vagus nerve stimulation (ta-VNS) in patients with epilepsy. A total of 150 patients were randomly divided into active stimulation group and control group. At baseline and 4, 12, and 20 weeks of stimulation, demographic information, seizure frequency, and adverse events were recorded; at 20 weeks, the patients underwent assessment of quality of life, Hamilton Anxiety and Depression scale, MINI suicide scale, and MoCA scale. Seizure frequency was determined according to the patient's seizure diary. Seizure frequency reduction > 50% was considered effective. During our study, the antiepileptic drugs were maintained at a constant level in all subjects. At 20 weeks, the responder rate was significantly higher in active group than in control group. The relative reduction of seizure frequency in the active group was significantly higher than that in the control group at 20 weeks. Additionally, no significant differences were shown in QOL, HAMA, HAMD, MINI, and MoCA score at 20 weeks. The main adverse events were pain, sleep disturbance, flu-like symptoms, and local skin discomfort. No severe adverse events were reported in active and control group. There were no significant differences in adverse events and severe adverse events between the two groups. The present study showed that ta-VNS is an effective and safe therapy for epilepsy. Furthermore, the benefit in QOL, mood, and cognitive state of ta-VNS needs further validation in the future study although no significant improvement was shown in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.